This clinical trial, together with {1,2}, helped firmly establish the implantable cardioverter defibrillator (ICD) in primary, as well as in secondary, prevention of sudden cardiac death. More recently a subcutaneous version of this device has emerged as a seemingly safer alternative. This Recommendation is of an article referenced in an F1000Prime Report also written by Lars Eckardt, Markus Bettin, Florian Reinke, Benjamin Rath and Julia Köbe.